Polymyalgia Rheumatica Clinical Trial
Official title:
Dose Reduction and Discontinuation of Prednisolone Using Structured Treat-to-target Taper in Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) has an incidence of approximately 1000/10^6 for persons more than 50 years. Treatment with prednisolone carries several significant adverse effects, and it is therefore essential to taper prednisolone as fast as possible. Systematic treatment strategies (treat-to-target) is the most important improvement of disease management for other rheumatic diseases such as rheumatoid arthritis in the last decades. Thus, the purpose is to investigate benefits and harms associated with a nurce led systematic prednisolone taper strategy at the department of rheumatology compared to individual treatment by discretion of the general practitioner. It is a 1-year open label randomised trial with a 1-year extension in 120 treatment naïve patients with PMR.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04972968 -
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
|
Phase 2 | |
| Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
| Terminated |
NCT03600818 -
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
|
Phase 3 | |
| Completed |
NCT00836810 -
Timed Release Tablet Prednisone in Polymyalgia Rheumatica
|
Phase 2/Phase 3 | |
| Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
| Completed |
NCT03263715 -
A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)
|
Phase 3 | |
| Recruiting |
NCT05935709 -
DANIsh VASculitis Database (DANIVAS)
|
||
| Not yet recruiting |
NCT02985424 -
Polymyalgia Rheumatica and Giant Cell Arteritis
|
N/A | |
| Completed |
NCT00138983 -
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
|
Phase 3 | |
| Recruiting |
NCT06130540 -
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
|
Phase 1 | |
| Recruiting |
NCT05767034 -
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
|
Phase 3 | |
| Terminated |
NCT01821040 -
A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR
|
Phase 3 | |
| Recruiting |
NCT00982332 -
Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica
|
N/A | |
| Recruiting |
NCT05312944 -
Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome
|
||
| Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
| Withdrawn |
NCT02899026 -
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
|
Phase 3 | |
| Not yet recruiting |
NCT06281236 -
A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)
|
Phase 1 | |
| Recruiting |
NCT03576794 -
Treatment With Leflunomide in Patients With Polymyalgia Rheumatica
|
Phase 3 | |
| Completed |
NCT05681676 -
Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
|
||
| Recruiting |
NCT05435781 -
Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
|
Phase 4 |